SCHEMBL5084415

SCHEMBL5084415

C=C(CCCCCCN)C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
THRB P10828 2/20 0.52
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
PLG P00747 1/20 0.52
ALOX15 P16050 1/20 0.52
SLC6A2 P23975 1/20 0.52
RECQL P46063 1/20 0.52
SLC6A3 Q01959 1/20 0.52
PAOX Q6QHF9 4/20 0.50
CYP2D6 P10635 1/20 0.48
NFKB1 P19838 1/20 0.48
BLM P54132 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
TSHR P16473 2/20 0.39
GABRR3 A8MPY1 1/20 0.39
GABRP O00591 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15846289 0.98 NFKB1 (0.50) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL639214 0.90
SCHEMBL17672227 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL730324 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL731200 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL1862317 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL732893 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL435733 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL1858134 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1
SCHEMBL1865622 0.90 LMNA (0.38) LMNATHRBKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028671-A1 Sequencing by Structure Assembly HARVARD COLLEGE (US) 2026-01-29 US disclosed
US-20250369043-A1 LINKERS AND METHODS FOR OPTICAL DETECTION AND SEQUENCING ULTIMA GENOMICS INC (US) 2025-12-04 US disclosed
EP-4655423-A1 INFERRING MICROORGANISM OF ORIGIN FOR ANTIMICROBIAL RESISTANCE MARKERS IN TARGETED METAGENOMICS Illumina, Inc. (US) 2025-12-03 EP disclosed
US-12467086-B2 Sequencing by structure assembly PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-11-11 US disclosed
US-20250277224-A1 COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2025-09-04 US disclosed
US-12378600-B2 Linkers and methods for optical detection and sequencing ULTIMA GENOMICS, INC. (US) 2025-08-05 US disclosed
US-12338474-B2 Compositions and methods for producing circular polyribonucleotides FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2025-06-24 US disclosed
US-20250188505-A1 PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A PROKARYOTIC SYSTEM FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) 2025-06-12 US disclosed
WO-2025097012-A1 METHODS OF SORTING SPERM BASED ON GENOTYPE MAVEN BONNIE E J (US) 2025-05-08 WO disclosed
US-20250129419-A1 REAGENTS FOR LABELING BIOMOLECULES AND USES THEREOF ULTIMA GENOMICS INC (US) 2025-04-24 US disclosed
CN-114007612-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
CN-114007611-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
CN-114007613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
CN-114007614-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-02-01 CN disclosed
US-20180340020-A1 PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-11-29 US disclosed
US-10072065-B2 Peptide-mediated delivery of immunoglobulins across the blood-brain barrier MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2018-09-11 US disclosed
US-20170058017-A1 PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-03-02 US disclosed
US-8715923-B2 Protein scaffolds and viral particles for detecting analytes THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2014-05-06 US disclosed
US-20080220408-A1 Non-enveloped virus particles comprising a plurality of detectable fluorescent labels for use in solid support for detecting preferential particles in solutions THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SE (US) 2008-09-11 US disclosed
WO-2006124044-A2 PROTEIN SCAFFOLDS AND VIRAL PARTICLES FOR DETECTING ANALYTES GEORGE MASON UNIVERSITY (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028671-A1 Sequencing by Structure Assembly POLL, CPSF7, POLM LMNA 202/4885THRB 717/4885KMT2A 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.